Experts explain how EZH2 fuels AR-inhibitor resistance in metastatic prostate cancer and why epigenetic targeting may restore response in trials.
Back
EZH2 Inhibition in ARPI-Resistant Metastatic Prostate Cancer: Mechanism, Evidence, and Clinical Application
Dr. Neeraj Agarwal (Huntsman Cancer Institute) and Dr. Alicia Morgans (Dana-Farber Cancer Institute) examine EZH2 inhibition as an investigational strategy in androgen receptor pathway inhibitor (ARPI)-resistant metastatic castration-resistant prostate cancer (mCRPC). The discussion explores the canonical and non-canonical roles of EZH2 in prostate cancer biology, including its function as a histone methyltransferase and as a co-activator of the androgen receptor (AR), and the rationale for combining EZH2 inhibitors with enzalutamide. The experts review early-phase efficacy and safety data for mevrometostat plus enzalutamide and detail the design of the phase 3 MEVPRO-1 and MEVPRO-2 trials, including patient populations, eligibility, endpoints, and dosing. Practical guidance is provided on adverse event management, trial referral pathways, patient communication about investigational therapy, and contextualizing mevrometostat among other EZH2-directed strategies. Tailored for genitourinary oncologists, urologists, and the multidisciplinary team.
EZH2 Inhibition in ARPI-Resistant Metastatic Prostate Cancer: Mechanism, Evidence, and Clinical Application
Episodes
All
All
New findings show EZH2 inhibition may not reverse lineage plasticity, but can rewire AR signaling and expand neuroendocrine tumor diversity.
New studies reveal EZH2 inhibition may not reverse prostate cancer lineage plasticity, instead fueling neuroendocrine diversity and AR rewiring.
How EZH2 inhibitors plus enzalutamide may restore AR therapy response, curb neuroendocrine shift, and delay prostate cancer resistance.
Explore MEV-Pro trials testing enzalutamide plus mevro metastate in mCRPC, from post-abiraterone to ARPI-naïve patients, aiming to delay resistance.
Inside MEV‑Pro trials: who qualifies for enzalutamide plus mevro metastate, and how the strategy targets mCRPC earlier to delay resistance.
Early Mepro trial data show mevorimetastat plus enzalutamide may extend rPFS in post-abiraterone mCRPC, with stronger PSA and response rates.
Explore mebrometastat plus enzalutamide side effects—GI toxicity, anemia, neutropenia—plus practical dose reductions and lab monitoring to keep patients on therapy.
Explore how an oral EZH2 inhibitor plus enzalutamide may fit early in mCRPC, offering broad use with fewer biomarker and safety limits.
Explore where EZH2 inhibitors pair with enzalutamide in mCRPC, offering an early, oral option with broad eligibility and fewer therapy restrictions.
EZH2 inhibitors reshape how cancer genes switch on or off, offering a non-chemotherapy approach that may boost and extend response to AR therapy.
EZH2 inhibitors reshape how cancer genes switch on or off, slowing growth and boosting response alongside AR therapy, unlike chemo’s cell-killing approach.
New EZH2 inhibitors, PROTAC degraders and combos aim to curb lineage plasticity, extending enzalutamide benefit in first-line mCRPC trials.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
2
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
3
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5